DE69623472T2 - Derivate von dolastatin, dreen herstellung un verwendung - Google Patents

Derivate von dolastatin, dreen herstellung un verwendung

Info

Publication number
DE69623472T2
DE69623472T2 DE69623472T DE69623472T DE69623472T2 DE 69623472 T2 DE69623472 T2 DE 69623472T2 DE 69623472 T DE69623472 T DE 69623472T DE 69623472 T DE69623472 T DE 69623472T DE 69623472 T2 DE69623472 T2 DE 69623472T2
Authority
DE
Germany
Prior art keywords
dreen
dolastatin
derivatives
production
dreen production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69623472T
Other languages
English (en)
Other versions
DE69623472D1 (de
Inventor
Andreas Haupt
Franz Emling
A Romerdahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Application granted granted Critical
Publication of DE69623472D1 publication Critical patent/DE69623472D1/de
Publication of DE69623472T2 publication Critical patent/DE69623472T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69623472T 1995-06-07 1996-06-03 Derivate von dolastatin, dreen herstellung un verwendung Expired - Lifetime DE69623472T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002392 WO1996040751A1 (en) 1995-06-07 1996-06-03 Novel dolastatin derivatives, their preparation and use

Publications (2)

Publication Number Publication Date
DE69623472D1 DE69623472D1 (de) 2002-10-10
DE69623472T2 true DE69623472T2 (de) 2003-08-21

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69623472T Expired - Lifetime DE69623472T2 (de) 1995-06-07 1996-06-03 Derivate von dolastatin, dreen herstellung un verwendung
DE69623992T Expired - Lifetime DE69623992T2 (de) 1995-06-07 1996-06-03 Derivate von dolestatin, deren herstellung und verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69623992T Expired - Lifetime DE69623992T2 (de) 1995-06-07 1996-06-03 Derivate von dolestatin, deren herstellung und verwendung

Country Status (33)

Country Link
US (1) US5831002A (de)
EP (2) EP0871656B1 (de)
JP (2) JP4221062B2 (de)
KR (2) KR100437986B1 (de)
CN (2) CN1182154C (de)
AR (2) AR003136A1 (de)
AT (2) ATE224910T1 (de)
AU (2) AU725170B2 (de)
BG (2) BG102125A (de)
BR (2) BR9609424A (de)
CA (2) CA2219819C (de)
CO (2) CO4700527A1 (de)
CZ (2) CZ293683B6 (de)
DE (2) DE69623472T2 (de)
DK (2) DK0871656T3 (de)
ES (2) ES2188759T3 (de)
HR (2) HRP960257A2 (de)
HU (2) HU228071B1 (de)
IL (2) IL122215A (de)
MX (2) MX9709147A (de)
MY (2) MY119042A (de)
NO (2) NO317670B1 (de)
NZ (2) NZ310444A (de)
PL (2) PL185762B1 (de)
PT (2) PT871656E (de)
RO (2) RO118953B1 (de)
SI (2) SI0832104T1 (de)
SK (1) SK282466B6 (de)
TR (2) TR199701545T1 (de)
TW (2) TW508357B (de)
UA (2) UA46776C2 (de)
WO (2) WO1996040751A1 (de)
ZA (2) ZA964710B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
EP2266607A3 (de) 1999-10-01 2011-04-20 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
WO2002088298A1 (en) 2001-04-27 2002-11-07 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
WO2003051835A2 (en) * 2001-12-18 2003-06-26 Proteologics, Inc. Methods and compositions for the inhibition of viral release
EP1531846A4 (de) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Konjugate aus ligand, linker und zytotoxischem agens sowie verwandte zusammensetzungen und verwendungsverfahren
US8568637B2 (en) 2004-08-02 2013-10-29 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
EP2049524A2 (de) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap-hemmer
NZ580271A (en) * 2007-04-12 2011-03-31 Scinopharm Taiwan Ltd Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
AU2011352145A1 (en) 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP6581774B2 (ja) * 2011-05-27 2019-09-25 アンブルックス, インコーポレイテッドAmbrx, Inc. 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法
EP3089757A1 (de) 2014-01-03 2016-11-09 AbbVie Inc. Feste antivirale darreichungsformen
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
UA45304C2 (uk) * 1992-05-20 2002-04-15 Басф Аг Похідні пептиду або їх солі, фармацевтична композиція
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
NZ310444A (en) 1999-11-29
HRP960257A2 (en) 1998-02-28
AU6124296A (en) 1996-12-30
IL122215A0 (en) 1998-04-05
CA2219818C (en) 2008-05-20
SK282466B6 (sk) 2002-02-05
US5831002A (en) 1998-11-03
ZA964710B (en) 1997-12-08
PL323726A1 (en) 1998-04-14
NO975711L (no) 1998-01-30
AR003136A1 (es) 1998-07-08
CZ293682B6 (cs) 2004-07-14
NO975711D0 (no) 1997-12-05
EP0871656B1 (de) 2002-09-25
ZA964711B (en) 1997-12-08
AU725170B2 (en) 2000-10-05
ATE224910T1 (de) 2002-10-15
CN1182154C (zh) 2004-12-29
CA2219819A1 (en) 1996-12-19
EP0871656A1 (de) 1998-10-21
CA2219819C (en) 2008-05-20
CN1187199A (zh) 1998-07-08
DK0871656T3 (da) 2003-01-27
CA2219818A1 (en) 1996-12-19
PL185763B1 (pl) 2003-07-31
RO119783B1 (ro) 2005-03-30
JPH11504652A (ja) 1999-04-27
WO1996040752A1 (en) 1996-12-19
MY124487A (en) 2006-06-30
CZ376597A3 (cs) 1998-06-17
TW424096B (en) 2001-03-01
EP0832104B1 (de) 2002-09-04
DE69623992T2 (de) 2003-05-22
CZ376397A3 (cs) 1998-06-17
KR19990022583A (ko) 1999-03-25
AR003427A1 (es) 1998-08-05
JPH11504653A (ja) 1999-04-27
EP0832104A1 (de) 1998-04-01
IL122216A (en) 2002-02-10
TW508357B (en) 2002-11-01
KR19990022582A (ko) 1999-03-25
AU6124196A (en) 1996-12-30
UA46775C2 (uk) 2002-06-17
CZ293683B6 (cs) 2004-07-14
HUP9801817A2 (hu) 1998-11-30
NO317670B1 (no) 2004-11-29
NO975710L (no) 1998-02-02
RO118953B1 (ro) 2004-01-30
PL185762B1 (pl) 2003-07-31
MX9709146A (es) 1998-03-31
ATE223431T1 (de) 2002-09-15
UA46776C2 (uk) 2002-06-17
HRP960277A2 (en) 1997-10-31
AU725164B2 (en) 2000-10-05
ES2188759T3 (es) 2003-07-01
CN1187198A (zh) 1998-07-08
DK0832104T3 (da) 2003-01-06
BR9609424A (pt) 2000-03-28
PT871656E (pt) 2002-12-31
JP4221062B2 (ja) 2009-02-12
HUP9801910A2 (hu) 1999-01-28
MY119042A (en) 2005-03-31
SI0832104T1 (en) 2003-08-31
MX9709147A (es) 1998-03-31
WO1996040751A1 (en) 1996-12-19
SI0871656T1 (en) 2003-08-31
NO318384B1 (no) 2005-03-14
HUP9801817A3 (en) 1999-06-28
ES2186783T3 (es) 2003-05-16
DE69623472D1 (de) 2002-10-10
SK165397A3 (en) 1998-10-07
HUP9801910A3 (en) 1999-06-28
DE69623992D1 (de) 2002-10-31
HU228073B1 (hu) 2012-09-28
PL323723A1 (en) 1998-04-14
HU228071B1 (hu) 2012-09-28
BG102125A (en) 1998-09-30
BR9609423A (pt) 1999-06-29
CN1182153C (zh) 2004-12-29
TR199701544T1 (xx) 1998-03-21
JP3957751B2 (ja) 2007-08-15
TR199701545T1 (xx) 1998-04-21
CO4700526A1 (es) 1998-12-29
IL122216A0 (en) 1998-04-05
NO975710D0 (no) 1997-12-05
KR100437986B1 (ko) 2004-09-18
CO4700527A1 (es) 1998-12-29
KR100437985B1 (ko) 2004-09-18
IL122215A (en) 2001-08-26
BG102152A (en) 1998-09-30
NZ310443A (en) 1999-10-28
PT832104E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
DE69623472T2 (de) Derivate von dolastatin, dreen herstellung un verwendung
DE69625857T2 (de) Siliconderivate, ihre Herstellung und Verwendung
DE69628195D1 (de) Verwendung von xyloglucanendotransglycosylase
DE59606486D1 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69804513T2 (de) Herstellung von zeolith-l
DE69420095T2 (de) Derivate von Polysacchariden, ihre Herstellung und Verwendung
DE69626462T2 (de) Herstellung von Gas
DE69604071D1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
DE69502001T2 (de) Herstellung von uranoxid
DE59604429D1 (de) Herstellung von difluorchlor- und dichloracetylchlorid
DE69611303T2 (de) Benzolsulfonamidderivate, ihre herstellung und ihre therapeutische verwendung
DE69623986T2 (de) Herstellung von Allomelanin
DE69502395D1 (de) Herstellung von triarylboran
DE69705849T2 (de) Herstellung von 3,5-lutidin
DE69702961D1 (de) Herstellung von 1,1-difluorethan
DE69615396D1 (de) Derivate von 5-naphthalin-1-yl-1,3-dioxanen, ihre herstellung und therapeutische anwendung
DE59606492D1 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69619812D1 (de) Kontinuierliche herstellung von 1,1-difluorethan
DE69611546D1 (de) Herstellung von 2,6-dimethylnaphthalin
DE69703422T2 (de) Herstellung von Aminophenolen
DE69707898T2 (de) Herstellung von bromierten indanen
DE69611551D1 (de) Herstellung von 6-brom-2-naphtholderivaten
DE69636713T8 (de) Supraleiter und ihre Vorläufer, ihre Herstellung und Verwendung von Supraleiter
DE69612122T2 (de) Herstellung von 6-brom-2-methoxynaphthalin und derivaten
DE69611552D1 (de) Herstellung von 6-brom-2-naphthol und derivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition